Philogen

Company Description

Founded in 1996, Philogen is an Italian-Swiss biotechnology company engaged in the discovery and development of biopharmaceutical products for the treatment of life-threatening conditions.

Philogen Group mainly discovers and develops targeted anti-cancer drugs, exploiting high-affinity ligands for tumor markers. These ligands – namely human monoclonal antibodies or small molecules – are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The main therapeutic strategy of the Group for the treatment of these diseases is the so-called “tumor targeting”.